专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

US20050118196A1 Novel therapeutic processes for establishing or enhancing an immunized state, and compositions useful therefor 审中-公开
标题翻译：用于建立或增强免疫状态的新型治疗方法及其有用的组合物
公开(公告)号：US20050118196A1
公开(公告)日：2005-06-02
申请号：US10470599
申请日：2003-12-08
申请人： Yaron Ilan , Elazar Rabbani , Dean Engelhardt , Israel Gotsman , James Donegan
发明人： Yaron Ilan , Elazar Rabbani , Dean Engelhardt , Israel Gotsman , James Donegan
IPC分类号： A61K35/12 , A61K38/095 , A61K39/00 , A61K39/21 , A61K39/29 , A61P31/00 , A61P31/12 , A61P31/18 , A61P35/00 , A61P37/02 , A61P37/04 , A61K39/12 , A61K39/02
CPC分类号： A61K39/0005 , A61K38/00 , A61K39/001 , A61K39/12 , A61K39/292 , A61K2035/122 , A61K2039/5152 , A61K2039/542 , A61K2039/57 , C12N2730/10134
摘要： This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination processes for preventing infections in subjects are also provided. The novel processes comprise introducing into or adminstering to a subject one or more antigens, or trained or adopted immune cells. These antigens or immune cells are capable of establishing or increasing at least one first specific immune response and decreasing at least one second specific immune response. Such responses include components, such as cellular immune reaction elements, humoral immune reaction elements and cytokines, the latter also encompassing interferons and lymphokines. Useful compositions are also provided by this invention.
摘要翻译：本发明提供了用于治疗应用的新方法，包括治疗携带感染性物质或具有受损的自身免疫或免疫病症受损的受试者。本文公开的治疗应用还涉及用含有癌细胞或恶性或癌细胞的恶性肿瘤治疗癌性受试者。还提供了预防受试者感染的疫苗接种过程。该新颖方法包括向受试者引入或施用一种或多种抗原或训练或采用的免疫细胞。这些抗原或免疫细胞能够建立或增加至少一种第一特异性免疫应答并减少至少一种第二特异性免疫应答。这些反应包括组分，如细胞免疫反应元件，体液免疫反应元件和细胞因子，后者还包括干扰素和淋巴因子。本发明也提供有用的组合物。

32. 发明申请

US20060019353A1 Protein-nucleic acid conjugate for producing specific nucleic acid 审中-公开
标题翻译：用于产生特异性核酸的蛋白质 - 核酸结合物
公开(公告)号：US20060019353A1
公开(公告)日：2006-01-26
申请号：US10717140
申请日：2003-11-18
申请人： Dean Engelhardt , Jannis Stayrianopoulos , Elazar Rabbani , James Donegan
发明人： Dean Engelhardt , Jannis Stayrianopoulos , Elazar Rabbani , James Donegan
IPC分类号： C12P19/34
CPC分类号： C12N15/10 , C12P19/34 , C12Q1/6844 , C12Q1/6853 , C12Q1/6858 , C12Q1/686 , C12Q1/6865 , C12Q2525/203 , C12Q2521/119
摘要： This invention provides inter alia an in vitro process for producing multiple specific nucleic acid copies in which the copies are produced under isostatic conditions, e.g., temperature, buffer and ionic strength, and independently of any requirement for introducing an intermediate structure for producing the copies. In other aspects, the invention provides in vitro processes for producing multiple specific nucleic acid copies in which the products are substantially free of any primer-coded sequences, such sequences having been substantially or all removed from the product to regenerate a primer binding site, thereby allowing new priming events to occur and multiple nucleic acid copies to be produced. This invention further provides a promoter-independent non-naturally occurring nucleic acid construct that produces a nucleic acid copy or copies without using or relying on any gene product that may be coded by the nucleic acid construct. Another aspect of this invention concerns a protein-nucleic acid construct in the form of a conjugate linked variously, e.g., covalent linkage, complementary nucleic acid base-pairing, nucleic acid binding proteins, or ligand receptor binding. Further disclosed in this invention is an in vivo process for producing a specific nucleic acid in which such a protein-nucleic acid construct conjugate is introduced into a cell. A still further aspect of the invention relates to a construct comprising a host promoter, second promoter and DNA sequence uniquely located on the construct. The host transcribes a sequence in the construct coding for a different RNA polymerase which after translation is capable of recognizing its cognate promoter and transcribing from a DNA sequence of interest in the construct with the cognate promoter oriented such that it does not promote transcription from the construct of the different RNA polymerase.
摘要翻译：本发明特别提供用于生产多种特异性核酸拷贝的体外方法，其中拷贝在等静压条件下，例如温度，缓冲液和离子强度下产生，并且独立于引入用于产生拷贝的中间结构的任何要求。在其它方面，本发明提供了用于产生多种特异性核酸拷贝的体外方法，其中产物基本上不含任何引物编码的序列，这些序列基本上或全部从产物中除去以再生引物结合位点，从而允许发生新的引发事件并产生多个核酸拷贝。本发明进一步提供了一种与天然存在的启动子相关的非天然存在的核酸构建体，其不使用或依赖于可由核酸构建体编码的任何基因产物产生核酸拷贝或拷贝。本发明的另一方面涉及以不同方式连接的缀合物形式的蛋白质 - 核酸构建体，例如共价连接，互补核酸碱基配对，核酸结合蛋白或配体受体结合。在本发明中进一步公开的是用于生产其中将这种蛋白质 - 核酸构建体缀合物引入细胞的特异性核酸的体内方法。本发明的另一方面涉及包含宿主启动子，第二启动子和唯一位于构建体上的DNA序列的构建体。宿主转录编码不同RNA聚合酶的构建体中的序列，其在翻译后能够识别其同源启动子并且从构建体中感兴趣的DNA序列转录成同源启动子定向，使得其不促进构建体的转录的不同RNA聚合酶。

33. 发明申请

US20050260226A1 Novel therapeutic processes for treating infectious agents by training or adoptive transfer of immune cells, and useful compositions therefor 审中-公开
标题翻译：用于通过训练或过继免疫细胞转移治疗感染因子的新型治疗方法及其有用的组合物
公开(公告)号：US20050260226A1
公开(公告)日：2005-11-24
申请号：US10470601
申请日：2003-12-08
申请人： Yaron Ilan , Elazar Rabbani , Dean Engelhardt , Israel Gotsman , James Donegan
发明人： Yaron Ilan , Elazar Rabbani , Dean Engelhardt , Israel Gotsman , James Donegan
IPC分类号： A61K35/12 , A61K38/095 , A61K39/00 , A61K39/21 , A61K39/29 , A61P31/00 , A61P31/12 , A61P31/18 , A61P35/00 , A61P37/02 , A61P37/04 , A61K39/12
CPC分类号： A61K39/0005 , A61K38/00 , A61K39/001 , A61K39/12 , A61K39/292 , A61K2035/122 , A61K2039/5152 , A61K2039/542 , A61K2039/57 , C12N2730/10134
摘要： This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination processes for preventing infections in subjects are also provided. The novel processes comprise introducing into or adminstering to a subject one or more antigens, or trained or adopted immune cells. These antigens or immune cells are capable of establishing or increasing at least one first specific immune response and decreasing at least one second specific immune response. Such responses include components, such as cellular immune reaction elements, humoral immune reaction elements and cytokines, the latter also encompassing interferons and lymphokines. Useful compositions are also provided by this invention.
摘要翻译：本发明提供了用于治疗应用的新方法，包括治疗携带感染性物质或具有受损的自身免疫或免疫病症受损的受试者。本文公开的治疗应用还涉及用含有癌细胞或恶性或癌细胞的恶性肿瘤治疗癌性受试者。还提供了预防受试者感染的疫苗接种过程。该新颖方法包括向受试者引入或施用一种或多种抗原或训练或采用的免疫细胞。这些抗原或免疫细胞能够建立或增加至少一种第一特异性免疫应答并减少至少一种第二特异性免疫应答。这些反应包括组分，如细胞免疫反应元件，体液免疫反应元件和细胞因子，后者还包括干扰素和淋巴因子。本发明也提供有用的组合物。

34. 发明申请

US20050255454A1 Novel therapeutic processes for enhancing immunized states of vaccinated subjects 审中-公开
标题翻译：用于增强免疫接种受试者的免疫状态的新型治疗方法
公开(公告)号：US20050255454A1
公开(公告)日：2005-11-17
申请号：US10470664
申请日：2003-12-08
申请人： Yaron Ilan , Elazar Rabbani , Dean Engelhardt , Israel Gotsman , James Donegan
发明人： Yaron Ilan , Elazar Rabbani , Dean Engelhardt , Israel Gotsman , James Donegan
IPC分类号： A61K35/12 , A61K38/095 , A61K39/00 , A61K39/21 , A61K39/29 , A61P31/00 , A61P31/12 , A61P31/18 , A61P35/00 , A61P37/02 , A61P37/04 , C12Q1/70 , A61K39/12
CPC分类号： A61K39/0005 , A61K38/00 , A61K39/001 , A61K39/12 , A61K39/292 , A61K2035/122 , A61K2039/5152 , A61K2039/542 , A61K2039/57 , C12N2730/10134
摘要： This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination processes for preventing infections in subjects are also provided. The novel processes comprise introducing into or adminstering to a subject one or more antigens, or trained or adopted immune cells. These antigens or immune cells are capable of establishing or increasing at least one first specific immune response and decreasing at least one second specific immune response. Such responses include components, such as cellular immune reaction elements, humoral immune reaction elements and cytokines, the latter also encompassing interferons and lymphokines. Useful compositions are also provided by this invention.
摘要翻译：本发明提供了用于治疗应用的新方法，包括治疗携带感染性物质或具有受损的自身免疫或免疫病症受损的受试者。本文公开的治疗应用还涉及用含有癌细胞或恶性或癌细胞的恶性肿瘤治疗癌性受试者。还提供了预防受试者感染的疫苗接种过程。该新颖方法包括向受试者引入或施用一种或多种抗原或训练或采用的免疫细胞。这些抗原或免疫细胞能够建立或增加至少一种第一特异性免疫应答并减少至少一种第二特异性免疫应答。这些反应包括组分，如细胞免疫反应元件，体液免疫反应元件和细胞因子，后者还包括干扰素和淋巴因子。本发明也提供有用的组合物。

35. 发明申请

US20050260560A1 Novel therapeutic processes for treating cancer with trained or adopted immune cells, and useful compositions therefor 审中-公开
标题翻译：用经过训练或采用的免疫细胞治疗癌症的新型治疗方法及其有用的组合物
公开(公告)号：US20050260560A1
公开(公告)日：2005-11-24
申请号：US10470603
申请日：2003-12-08
申请人： Yaron Ilan , Elazar Rabbani , Dean Engelhardt , Isarel Gotsman , James Donegan
发明人： Yaron Ilan , Elazar Rabbani , Dean Engelhardt , Isarel Gotsman , James Donegan
IPC分类号： A61K35/12 , A61K38/095 , A61K39/00 , A61K39/21 , A61K39/29 , A61P31/00 , A61P31/12 , A61P31/18 , A61P35/00 , A61P37/02 , A61P37/04 , C12Q1/70 , A61K39/12
CPC分类号： A61K39/0005 , A61K38/00 , A61K39/001 , A61K39/12 , A61K39/292 , A61K2035/122 , A61K2039/5152 , A61K2039/542 , A61K2039/57 , C12N2730/10134
摘要： This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination processes for preventing infections in subjects are also provided. The novel processes comprise introducing into or adminstering to a subject one or more antigens, or trained or adopted immurie cells. These antigens or immune cells are capable of establishing or increasing at least one first specific immune response and decreasing at least one second specific immune response. Such responses include components, such as cellular immune reaction elements, humoral immune reaction elements and cytokines, the latter also encompassing interferons and lymphokines. Useful compositions are also provided by this invention.
摘要翻译：本发明提供了用于治疗应用的新方法，包括治疗携带感染性物质或具有受损的自身免疫或免疫病症受损的受试者。本文公开的治疗应用还涉及用含有癌细胞或恶性或癌细胞的恶性肿瘤治疗癌性受试者。还提供了预防受试者感染的疫苗接种过程。该新颖的方法包括向受试者介绍或管理一种或多种抗原，或训练或采用的无菌细胞。这些抗原或免疫细胞能够建立或增加至少一种第一特异性免疫应答并减少至少一种第二特异性免疫应答。这些反应包括组分，如细胞免疫反应元件，体液免疫反应元件和细胞因子，后者还包括干扰素和淋巴因子。本发明也提供有用的组合物。

36. 发明申请

US20050147586A1 Novel therapeutic processes and useful compositions therefor 有权
标题翻译：新颖的治疗方法及其有用的组合物
公开(公告)号：US20050147586A1
公开(公告)日：2005-07-07
申请号：US10470611
申请日：2003-12-08
申请人： Yaron Ilan , Elazar Rabbani , Dean Engelhardt , Israel Gotsman , James Donegan
发明人： Yaron Ilan , Elazar Rabbani , Dean Engelhardt , Israel Gotsman , James Donegan
IPC分类号： A61K35/12 , A61K38/11 , A61K39/00 , A61K39/21 , A61K39/29 , A61P31/00 , A61P31/12 , A61P31/18 , A61P35/00 , A61P37/02 , A61P37/04 , A61K39/02 , A61K38/19
CPC分类号： A61K39/0005 , A61K38/00 , A61K39/001 , A61K39/12 , A61K39/292 , A61K2035/122 , A61K2039/5152 , A61K2039/542 , A61K2039/57 , C12N2730/10134
摘要： This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination processes for preventing infections in subjects are also provided. The novel processes comprise introducing into or adminstering to a subject one or more antigens, or trained or adopted immune cells. These antigens or immune cells are capable of establishing or increasing at least one first specific immune response and decreasing at least one second specific immune response. Such responses include components, such as cellular immune reaction elements, humoral immune reaction elements and cytokines, the latter also encompassing interferons and lymphokines. Useful compositions are also provided by this invention.
摘要翻译：本发明提供了用于治疗应用的新方法，包括治疗携带感染性物质或具有受损的自身免疫或免疫病症受损的受试者。本文公开的治疗应用还涉及用含有癌细胞或恶性或癌细胞的恶性肿瘤治疗癌性受试者。还提供了预防受试者感染的疫苗接种过程。该新颖方法包括向受试者引入或施用一种或多种抗原或训练或采用的免疫细胞。这些抗原或免疫细胞能够建立或增加至少一种第一特异性免疫应答并减少至少一种第二特异性免疫应答。这些反应包括组分，如细胞免疫反应元件，体液免疫反应元件和细胞因子，后者还包括干扰素和淋巴因子。本发明也提供有用的组合物。

37. 发明授权

US4144834A Defrost indicator 失效
标题翻译：除霜指示器
公开(公告)号：US4144834A
公开(公告)日：1979-03-20
申请号：US754847
申请日：1976-12-27
申请人： James Donegan
发明人： James Donegan
IPC分类号： G01K11/06
CPC分类号： G01K11/06
摘要： A thaw-indicating device that is visibly positioned in a package of frozen food so to warn a consumer if the food item has ever been subjected to being thawed, and thus being spoiled even if refrozen subsequently; the device consisting of a transparent plastic capsule having a sealed singular compartment in one end of which there is a colorless, clear, frozen ice and in the other end of which there is a powdered dye that is soluble in water, so that if the ice melts into water due to thawing temperatures the entire interior of the capsule is visibly colored.
摘要翻译：一种解冻指示装置，可视地定位在冷冻食品包装中，以便如果食品已经被解冻，就向消费者发出警告，即使后来被重新冷冻也被破坏; 该装置由透明塑料胶囊组成，该透明塑料胶囊的一端具有密封的单一隔室，其中有一个无色透明的冰冻冰，另一端则有可溶于水的粉状染料，因此如果冰由于解冻温度，胶囊的整个内部可见色彩，因而融入水中。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式